Xilio Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $43.8M | $6.3M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $56.0M | $41.2M |
| SG&A Expense | $29.7M | $24.8M |
| Operating Income | $-42.0M | $-60.6M |
| Operating Margin | -95.9% | -954.9% |
| Interest Expense | — | — |
| Pretax Income | $-35.0M | $-58.2M |
| Income Tax Expense | $0 | $0 |
| Net Income | $-35.0M | $-58.2M |
| Net Margin | -80.1% | -918.0% |
| EPS (Basic) | $-4.19 | $-15.24 |
| EPS (Diluted) | $-4.19 | $-15.24 |
| Shares Outstanding (Basic) | 8.4M | 3.8M |
| Shares Outstanding (Diluted) | 8.4M | 3.8M |
| Dividends Per Share | — | — |